Novanta Inc., together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide. Its Photonics segment offers photonics-based solutions, including laser scanning and beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products for photonics-based applications, such as industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The company's Vision segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless, recorder, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. Its Precision Motion segment offers optical and inductive encoders, precision motors, motion control sub-assemblies, servo drives, air bearings, and air bearing spindles. The company sells its products through its direct sales force, resellers, distributors, and system integrators under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was founded in 1968 and is headquartered in Bedford, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: novanta.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/11/2022 | Mkt Perform → Outperform | William Blair |
William Blair upgraded Novanta from Mkt Perform to Outperform
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
Third Quarter 2024 GAAP Revenue of $244 million Third Quarter 2024 GAAP Net Income of $19 million Third Quarter 2024 GAAP Diluted Earnings Per Share of $0.53 Third Quarter 2024 Adjusted Earnings Per Share of $0.85 Third Quarter 2024 Adjusted EBITDA of $57 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2024. Financial Highlights Three Months Ended (In millions, except per share amounts) September 27, September 29, 2024 2023 GAAP
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer is scheduled to present at the Baird 2024 Global Industrial Conference on Wednesday, November 13, 2024, in Chicago, Illinois. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to solve co
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2024 results on Tuesday, November 5, 2024. The Company will host a conference call on Tuesday, November 5, 2024, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the cal
Sends Letter to Shareholders Reiterating Why Voting for Both Politan's "Highly Credible and Capable" Nominees Is Essential in Order to Safeguard Shareholder Value and Realize Masimo's Potential Highlights Key Facts Brought to Light During Discovery Process and Remains Confident That Masimo's Frivolous Legal Claims and Efforts to Reject Politan's Nomination Notice Will Be Defeated Shareholders Can Vote for Politan's Independent Nominees, Darlene Solomon and William Jellison, on the WHITE Card and Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Compan
Second Quarter 2024 GAAP Revenue of $236 million Second Quarter 2024 GAAP Net Income of $13.8 million Second Quarter 2024 GAAP Diluted Earnings Per Share of $0.38 Second Quarter 2024 Adjusted Earnings Per Share of $0.73 Second Quarter 2024 Adjusted EBITDA of $51 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2024. Financial Highlights Three Months Ended (In millions, except per share amounts) June 28, June 30, 2024 2023 GAAP
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer, is scheduled to present at Baird's 2024 Global Healthcare Conference on Tuesday, September 10, 2024, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to solve complex
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2024 results on Tuesday, August 6, 2024. The Company will host a conference call on Tuesday, August 6, 2024, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the call
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at the CJS Securities 24th Annual New Ideas Summer Conference on Wednesday, July 10, 2024, in White Plains, New York. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to
First Quarter 2024 GAAP Revenue of $231 million First Quarter 2024 GAAP Net Income of $15 million First Quarter 2024 GAAP Diluted Earnings Per Share of $0.41 First Quarter 2024 Adjusted Earnings Per Share of $0.74 First Quarter 2024 Adjusted EBITDA of $50 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2024. Financial Highlights Three Months Ended (In millions, except per share amounts) March 29, March 31, 2024 2023
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Third Quarter 2024 GAAP Revenue of $244 million Third Quarter 2024 GAAP Net Income of $19 million Third Quarter 2024 GAAP Diluted Earnings Per Share of $0.53 Third Quarter 2024 Adjusted Earnings Per Share of $0.85 Third Quarter 2024 Adjusted EBITDA of $57 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2024. Financial Highlights Three Months Ended (In millions, except per share amounts) September 27, September 29, 2024 2023 GAAP
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2024 results on Tuesday, November 5, 2024. The Company will host a conference call on Tuesday, November 5, 2024, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the cal
Second Quarter 2024 GAAP Revenue of $236 million Second Quarter 2024 GAAP Net Income of $13.8 million Second Quarter 2024 GAAP Diluted Earnings Per Share of $0.38 Second Quarter 2024 Adjusted Earnings Per Share of $0.73 Second Quarter 2024 Adjusted EBITDA of $51 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2024. Financial Highlights Three Months Ended (In millions, except per share amounts) June 28, June 30, 2024 2023 GAAP
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2024 results on Tuesday, August 6, 2024. The Company will host a conference call on Tuesday, August 6, 2024, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the call
First Quarter 2024 GAAP Revenue of $231 million First Quarter 2024 GAAP Net Income of $15 million First Quarter 2024 GAAP Diluted Earnings Per Share of $0.41 First Quarter 2024 Adjusted Earnings Per Share of $0.74 First Quarter 2024 Adjusted EBITDA of $50 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2024. Financial Highlights Three Months Ended (In millions, except per share amounts) March 29, March 31, 2024 2023
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its first quarter 2024 results on Tuesday, May 7, 2024. The Company will host a conference call on Tuesday, May 7, 2024, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the call on the
Full Year 2023 GAAP Revenue of $882 million Full Year 2023 GAAP Net Income of $73 million Full Year 2023 GAAP Diluted Earnings Per Share of $2.02 Full Year 2023 Adjusted Earnings Per Share of $3.02 Full Year 2023 Adjusted EBITDA of $196 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the fourth quarter and full year 2023. Financial Highlights Three Months Ended December 31, Year Ended December 31, (In millions, except per share amounts) 2023 2022
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its fourth quarter and full year 2023 results on Wednesday, February 28, 2024. The Company will host a conference call on Wednesday, February 28, 2024, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after th
Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has completed the acquisition of Motion Solutions. "Motion Solutions is an excellent strategic fit to Novanta. Motion Solutions offers high-precision, customized precision motion subsystems and components to market-leading OEMs, largely centered on medical and life sciences applications. They are a market leading business, and their team shares a passion for customers, innovation, and solving complex technical challenges," said Matthijs Glastra, Chair and Chief Executive Officer of Novanta. "By acquiring Motion Solutions,
Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has entered into a definitive agreement to acquire Motion Solutions, a leading provider of highly engineered integrated solutions, for cash consideration of $189 million, subject to customary purchase price adjustments and closing conditions, including applicable regulatory approvals. Motion Solutions is a trusted engineering partner to market-leading original equipment manufacturers ("OEMs") in medical, life sciences, and advanced industrial applications. Motion Solutions designs and manufactures high-precision, customiz
10-Q - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
10-Q - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
SD - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
10-Q - NOVANTA INC (0001076930) (Filer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
3 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
Novanta's (NYSE:NOVT) short percent of float has risen 4.95% since its last report. The company recently reported that it has 1.57 million shares sold short, which is 5.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 16.25 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is im
Novanta's (NYSE:NOVT) short percent of float has fallen 5.04% since its last report. The company recently reported that it has 1.49 million shares sold short, which is 5.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 15.07 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is i
Financial Guidance For the second quarter of 2024, the Company expects GAAP revenue of approximately $230 million to $235 million. The Company expects Adjusted Gross Profit Margin to be approximately 46.0% to 46.3%. The Company expects Adjusted EBITDA to be in the range of $48 million to $50 million and Adjusted Diluted EPS to be in the range of $0.68 to $0.74. The Company's guidance assumes no significant changes in foreign exchange rates.
Novanta (NASDAQ:NOVT) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.58 by 27.59 percent. The company reported quarterly sales of $230.916 million which beat the analyst consensus estimate of $227.881 million by 1.33 percent. This is a 5.38 percent increase over sales of $219.126 million the same period last year.
Novanta's (NYSE:NOVT) short percent of float has fallen 4.01% since its last report. The company recently reported that it has 1.57 million shares sold short, which is 5.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 12.89 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is i
Novanta (NASDAQ:NOVT) reported quarterly earnings of $0.63 per share which met the analyst consensus estimate. This is a 16 percent decrease over earnings of $0.75 per share from the same period last year. The company reported quarterly sales of $211.57 million which beat the analyst consensus estimate of $210.69 million by 0.42 percent. This is a 3.12 percent decrease over sales of $218.37 million the same period last year.
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. • Golden Ocean Group (NASDAQ:GOGL) is likely to report quarterly earnings at $0.27 per share on revenue of $193.12 million. • Wallbox (NYSE:WBX) is likely to report earnings for its fourth quarter. • Immunocore Hldgs (NASDAQ:IMCR) is estimated to report quarterly loss at $0.28 per share on revenue of $67.23 million. • Royal Bank of Canada (NYSE:RY) is likely to report quarterly earnings at $2.08 per share on revenue of $9.95 billion. • TG Therapeutics (NASDAQ:TGTX) is likely to report quarterly loss at $0.10 per share on revenue of $40.06 mil
Novanta's (NYSE:NOVT) short percent of float has fallen 9.19% since its last report. The company recently reported that it has 1.64 million shares sold short, which is 5.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 14.37 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is i